SCHEMBL2789930

SCHEMBL2789930

Cc1cc(S(=O)(=O)C(F)(F)F)ccc1NC(=O)c1c(Cl)ccc(C(C)(C)C)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
TAS1R2 Q8TE23 2/20 0.42
CCR8 P51685 1/20 0.39
BCL2 P10415 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
CNR2 P34972 2/20 0.37
PDK1 Q15118 3/20 0.36
PDK2 Q15119 3/20 0.36
PDK3 Q15120 3/20 0.36
PDK4 Q16654 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CA9 Q16790 1/20 0.36
P2RX1 P51575 1/20 0.36
CXCR2 P25025 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786864 0.92 MEN1 (0.51) MEN1KMT2ACA1CA2PDK1
SCHEMBL2787811 0.89 MEN1 (0.46) MEN1KMT2ATAS1R3TAS1R1TAS1R2
SCHEMBL2787749 0.88 MEN1 (0.46) MEN1KMT2ACA1CA2PDK1
SCHEMBL2789440 0.84 CA2 (0.48) MEN1KMT2ACA1CA2PDK1
SCHEMBL2787334 0.83 MEN1 (0.39) MEN1KMT2ACCR8CA1CA2
SCHEMBL2787294 0.83 MEN1 (0.50) MEN1KMT2ACA1CA2PDK1
SCHEMBL2787739 0.82 MEN1 (0.45) MEN1KMT2ACA1CA2PDK1
SCHEMBL2791245 0.81 MEN1 (0.46) MEN1KMT2ACA1CA2PDK1
SCHEMBL2788787 0.81 KMT2A (0.44) MEN1KMT2ACA1CA2LMNA
SCHEMBL2787774 0.81 MEN1 (0.44) MEN1KMT2ACA1CA2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US claimed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 EP claimed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 WO claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US disclosed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US disclosed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A MEN1 4083/4885KMT2A 3302/4885TAS1R3 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.